88889-14-9 Fosinopril sodium AKSci H524
 
 
Loading Please Wait...
  H524    AKSci Reference Standard
Fosinopril sodium
, 98% (HPLC)
 
Eosinopril
(2S,4S)-4-cyclohexyl-1-(2-{[2-methyl-1-(propanoyloxy)propoxy](4-phenylbutyl)phosphoryl}acetyl)pyrrolidine-2-carboxylic acid
Acecor
more..




IDENTITY
CAS Number:88889-14-9
MDL Number:MFCD00897699
MF:C30H45NNaO7P
MW:585.64
SPECIFICATIONS & PROPERTIES
Purity:98% (HPLC)
Spectra:FT-IR, LCMS, HPLC
Physical Form:White to off-white powder
Melting Point:190-192°C
Long-Term Storage:Store long-term at -20°C

BIOLOGICAL INFO
Application(s):Enzyme (ACE) inhibitor

REVIEW

 There are two isoforms of ACE: the somatic isoform, which exists as a glycoprotein comprised of a single polypeptide chain of 1277; and the testicular isoform, which has a lower molecular mass and is thought to play a role in sperm maturation and binding of sperm to the oviduct epithelium. Somatic ACE has two functionally active domains, N and C, which arise from tandem gene duplication. Although the two domains have high sequence similarity, they play distinct physiological roles. The C-domain is predominantly involved in blood pressure regulation while the N-domain plays a role in hematopoietic stem cell differentiation and proliferation. ACE inhibitors bind to and inhibit the activity of both domains, but have much greater affinity for and inhibitory activity against the C-domain. Fosinoprilat, the active metabolite of fosinopril, competes with ATI for binding to ACE and inhibits and enzymatic proteolysis of ATI to ATII. Decreasing ATII levels in the body decreases blood pressure by inhibiting the pressor effects of ATII as described in the Pharmacology section above. Fosinoprilat also causes an increase in plasma renin activity likely due to a loss of feedback inhibition mediated by ATII on the release of renin and/or stimulation of reflex mechanisms via baroreceptors.

REFERENCES
[1]David D, Jallad N, Germino FW, Willett MS, de Silva J, Weidner SM, Mills DJ: A Comparison of the Cough Profile of Fosinopril and Enalapril in Hypertensive Patients with a History of ACE Inhibitor-Associated Cough. Am J Ther. 1995 Oct;2(10):806-813.
[2] Sharma S, Deitchman D, Eni JS, Gelperin K, Ilgenfritz JP, Blumenthal M: The hemodynamic effects of long-term ACE inhibition with fosinopril in patients with heart failure. Fosinopril Hemodynamics Study Group. Am J Ther. 1999 Jul;6(4):181-9.

GHS

Pictograms

Signal Word
Warning

Hazard Statements
H315; H319; H335

Precautionary Statements
P261; P264; P271; P280; P302+P352; P304+P340; P305+P351+P338; P312; P321; P332+P313; P337+P313; P362; P403+P233; P405; P501


RELATED PRODUCTS
H524Fosinopril sodium
K761Fosinopril

Current as of June 25, 2019

AKSci Reference Standards are high-purity, low-impurity compounds suitable for use as standards.


Download SDS

CATEGORIES

 APIs and Bioactives > ACE Inhibitors


PubChem